inetetamab

{
  "id": "MLC-T-ONC-014450",
  "term": "inetetamab",
  "field": "Oncology and biomedicine",
  "definition": "An Fc-engineered monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential immunomodulating and antineoplastic activities. Upon administration, inetetamab targets and specifically binds to HER2 on tumor cells, thereby blocking HER2-mediated signaling. This may inhibit proliferation of HER2-expressing tumor cells. In addition, the Fab region of inetetamab may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.",
  "synonyms": [
    "trastuzumab analogue inetetamab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/inetetamab/"
}